Beta‑Blocker Therapy and the Risk of New‑Onset Type 2 Diabetes

Magnitude of Diabetes Risk

• Beta‑blocker use is associated with a 22 % higher risk of developing type 2 diabetes (relative risk 1.22; 95 % CI 1.12–1.33) compared with non‑diuretic antihypertensive agents, based on a meta‑analysis of 12 studies involving 94 492 patients – moderate‑quality evidence. 1

• The diabetes risk is especially pronounced in older adults, rises with longer duration of therapy, and is highest with atenolol – derived from the same meta‑analysis. 1

• Higher baseline body‑mass index, elevated fasting glucose, and higher systolic and diastolic blood pressures independently predict diabetes onset in patients receiving beta‑blockers – moderate‑quality evidence from the meta‑analysis. 1

Impact on Cardiovascular Outcomes

• In the ASCOT trial, an amlodipine‑based regimen reduced cardiovascular events by 14 % and stroke incidence by 25 % relative to an atenolol‑based regimen in patients with diabetes, indicating that avoiding beta‑blockers when alternatives exist may improve outcomes – high‑quality randomized trial. 1

• Beta‑blocker therapy was linked to a 15 % increased risk of stroke (RR 1.15; 95 % CI 1.01–1.30) and showed no reduction in all‑cause mortality or myocardial infarction in the same meta‑analysis, suggesting limited benefit for stroke prevention in this context – moderate‑quality evidence. 1

• The ALLHAT trial found a higher incidence of diabetes with chlorthalidone than with lisinopril or amlodipine, yet changes in fasting plasma glucose over two years did not correlate with subsequent coronary heart disease or stroke, underscoring that glucose rise alone may not translate into excess cardiovascular events – high‑quality randomized trial. 1

Guideline Recommendations for Systolic Heart Failure

• The European Society of Cardiology (ESC) states that three neuro‑hormonal antagonists—an ACE inhibitor or ARB, a beta‑blocker, and a mineralocorticoid receptor antagonist—are essential for all patients with systolic heart failure (LVEF ≤ 40 %), including those with diabetes – Class I, Level A recommendation. 2

• MERIT‑HF trial data show that beta‑blockers lower mortality and hospital admissions in diabetic heart‑failure patients to a similar extent as in non‑diabetic patients, confirming the mortality benefit is preserved across glycaemic status – high‑quality randomized trial. 2

• Two meta‑analyses report that beta‑blocker therapy in diabetic heart‑failure patients improves mortality risk (relative risk 0.84 vs 0.72 without beta‑blocker) – moderate‑quality evidence. 2

• The ESC recommends metoprolol succinate (extended‑release), bisoprolol, or carvedilol as the preferred beta‑blockers for heart‑failure patients with diabetes – Class I, Level A. 2

Practical Recommendations for Hypertension (Without Heart Failure)

• For hypertension in patients without heart failure, beta‑blockers should not be used as first‑line therapy; ACE inhibitors, ARBs, or calcium‑channel blockers are preferred because they lower the risk of new‑onset diabetes – moderate‑quality evidence from the meta‑analysis. 1

• When beta‑blockade is unavoidable, vasodilating agents (e.g., carvedilol or nebivolol) are favored over traditional non‑vasodilating beta‑blockers, although this specific recommendation lacks a cited reference in the current source and is therefore omitted.

Safety Considerations in Diabetic Patients

• Beta‑blockers can mask typical hypoglycaemia symptoms such as tremor and palpitations while preserving sweating, creating a heightened risk of severe hypoglycaemia in insulin‑treated individuals – high‑quality evidence from ESC‑endorsed data. 2

Beta Blocker Effects on Glucose Metabolism

Mechanism and Degree of Hyperglycemia

• Nonselective beta blockers, such as propranolol, lower HDL cholesterol, increase triglycerides, and may cause type-2 diabetes in patients with hypertension, according to the American Heart Association 3, 4
• First- and second-generation beta blockers are associated with increased incidence of new-onset diabetes, demonstrated in several RCTs including LIFE and ASCOT trials, with a risk range of 15% to 29% in large clinical trials, as reported by the American College of Cardiology 3, 4, 5, 6
• The American College of Cardiology recommends that patients with metabolic syndrome or diabetes requiring beta blockade should choose vasodilating beta blockers, such as carvedilol or nebivolol, over traditional agents, due to their neutral or favorable effects on metabolic profiles 5, 6, 7

Clinical Significance and Context

• The clinical importance of beta-blocker-induced hyperglycemia is uncertain, as it could simply represent earlier unmasking of latent type-2 diabetes, which would then receive more intensified preventive treatment, according to the American Heart Association 3, 4
• A more clinically dangerous effect than hyperglycemia is that beta blockers mask symptoms of hypoglycemia, particularly in patients with type-1 diabetes or those treated with insulin, as warned by the FDA and reported by the American College of Cardiology 3, 4, 7

Practical Recommendations

• For patients with metabolic syndrome or diabetes requiring beta blockade, the American College of Cardiology recommends choosing vasodilating beta blockers, such as carvedilol or nebivolol, over traditional agents, due to their neutral or favorable effects on metabolic profiles 7
• If vasodilating agents are not available or appropriate, the American College of Cardiology suggests using beta-1 selective agents, such as metoprolol or bisoprolol, rather than nonselective agents, such as propranolol, to minimize the risk of hyperglycemia and hypoglycemia masking 7
• Careful monitoring of blood glucose is essential when using any beta-blocker in patients with diabetes, as recommended by the American Diabetes Association and reported by the American College of Cardiology 7

Beta‑Blocker Use in Type 2 Diabetes – Evidence‑Based Recommendations

Post‑Myocardial Infarction (Diabetes)

• Atenolol is at least as effective as ACE‑inhibition for preventing macrovascular and microvascular complications in hypertensive patients with type 2 diabetes. This conclusion is based on the UK Prospective Diabetes Study (UKPDS), a large randomized trial that enrolled 5,102 participants and followed them for 10 years, providing Level A evidence. 8

Hypertension Management in Diabetes

• The 2019 European Society of Cardiology (ESC) guidelines recommend using RAAS blockers (ACE‑I/ARBs) rather than beta‑blockers as first‑line therapy for blood‑pressure control in pre‑diabetes or diabetes, while acknowledging that beta‑blockers remain essential for heart‑failure treatment. This recommendation carries a Class I, Level A rating. 9

• ESC guidelines advise that beta‑blockers should not be prescribed as first‑line monotherapy for uncomplicated hypertension in patients with diabetes; they should be reserved for compelling indications such as post‑myocardial‑infarction or heart‑failure management. This guidance is also Class I, Level A. 9